Why now

Pharma is buying the gut. In 2024 Lilly paid ~$3.2B for Morphic, AbbVie up to ~$213M for Landos, Novo Nordisk licensed a gut–brain molecule from Kallyope, and Nestlé Health Science took VOWST outright.

The market

  • $19.9B → ~$37B: gut health supplements, 2025–2033. TRI-04 enters here.
  • $11B → ~$24B: cognitive gut–brain, 2024–2030. TRI-01 enters here.

What we have

  • Two products, one engine. TRI-04 for metabolic health, first US product 2027. TRI-01 for brain and blood sugar. Women's health next. Products →
  • Human evidence. A first in-human pilot on TRI-04; TRI-01 tested in living human gut communities. Evidence →
  • Manufacturing. Process optimized with Bühler, on a line that makes hundreds of kilograms.
  • Customers. 7 signed LOIs, including a top-4 global ingredient company. Our ingredient is inside products at MISTA Demo Day.
  • Protection. Patent filed, favorable EPO opinion, trade-secret process, and a private dataset that grows with every run. IP →
  • A fast path to revenue. Self-affirmed GRAS, feasibility positive; first US product 2027.
  • The team. Two PhD founders, 18+ years each across Sanofi, Rejuveron, InSphero, dsm-firmenich and J&J. Company →